vs
安捷伦科技（A）与Surgery Partners, Inc.（SGRY）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是Surgery Partners, Inc.的2.0倍（$1.8B vs $885.0M）。安捷伦科技净利率更高（17.0% vs -1.7%，领先18.7%）。安捷伦科技同比增速更快（7.0% vs 2.4%）。安捷伦科技自由现金流更多（$175.0M vs $90.6M）。过去两年Surgery Partners, Inc.的营收复合增速更高（11.1% vs 6.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Surgery Partners, Inc.（NASDAQ代码：SGRY）旗下的United Surgical Partners International（USPI）是美国领先的日间手术护理服务商，总部位于得克萨斯州达拉斯，由唐·斯廷于1998年创立，专注于为患者提供便捷、高效的门诊外科医疗服务，运营多家合规手术中心，覆盖美国多地医疗需求场景。
A vs SGRY — 直观对比
营收规模更大
A
是对方的2.0倍
$885.0M
营收增速更快
A
高出4.6%
2.4%
净利率更高
A
高出18.7%
-1.7%
自由现金流更多
A
多$84.4M
$90.6M
两年增速更快
SGRY
近两年复合增速
6.9%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $885.0M |
| 净利润 | $305.0M | $-15.0M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | 12.5% |
| 净利率 | 17.0% | -1.7% |
| 营收同比 | 7.0% | 2.4% |
| 净利润同比 | -4.1% | 86.2% |
| 每股收益（稀释后） | $1.07 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASGRY
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $885.0M | ||
| Q3 25 | $1.7B | $821.5M | ||
| Q2 25 | $1.7B | $826.2M | ||
| Q1 25 | $1.7B | $776.0M | ||
| Q4 24 | $1.7B | $864.4M | ||
| Q3 24 | $1.6B | $770.4M | ||
| Q2 24 | $1.6B | $762.1M |
净利润ASGRY
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-15.0M | ||
| Q3 25 | $336.0M | $-22.7M | ||
| Q2 25 | $215.0M | $-2.5M | ||
| Q1 25 | $318.0M | $-37.7M | ||
| Q4 24 | $351.0M | $-108.5M | ||
| Q3 24 | $282.0M | $-31.7M | ||
| Q2 24 | $308.0M | $-15.5M |
毛利率ASGRY
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率ASGRY
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 12.5% | ||
| Q3 25 | 20.7% | 12.9% | ||
| Q2 25 | 18.0% | 13.5% | ||
| Q1 25 | 22.4% | 8.0% | ||
| Q4 24 | 24.0% | 14.7% | ||
| Q3 24 | 21.1% | 7.9% | ||
| Q2 24 | 23.1% | 11.1% |
净利率ASGRY
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -1.7% | ||
| Q3 25 | 19.3% | -2.8% | ||
| Q2 25 | 12.9% | -0.3% | ||
| Q1 25 | 18.9% | -4.9% | ||
| Q4 24 | 20.6% | -12.6% | ||
| Q3 24 | 17.9% | -4.1% | ||
| Q2 24 | 19.6% | -2.0% |
每股收益（稀释后）ASGRY
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.11 | ||
| Q3 25 | $1.18 | $-0.18 | ||
| Q2 25 | $0.75 | $-0.02 | ||
| Q1 25 | $1.11 | $-0.30 | ||
| Q4 24 | $1.23 | $-0.86 | ||
| Q3 24 | $0.97 | $-0.25 | ||
| Q2 24 | $1.05 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $239.9M |
| 总债务越低越好 | $3.0B | $3.6B |
| 股东权益账面价值 | $6.9B | $1.7B |
| 总资产 | $12.8B | $8.1B |
| 负债/权益比越低杠杆越低 | 0.44× | 2.10× |
8季度趋势，按日历期对齐
现金及短期投资ASGRY
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $239.9M | ||
| Q3 25 | $1.5B | $203.4M | ||
| Q2 25 | $1.5B | $250.1M | ||
| Q1 25 | $1.5B | $229.3M | ||
| Q4 24 | $1.3B | $269.5M | ||
| Q3 24 | $1.8B | $221.8M | ||
| Q2 24 | $1.7B | $213.5M |
总债务ASGRY
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $3.6B | ||
| Q3 25 | $3.4B | $3.5B | ||
| Q2 25 | $3.3B | $3.5B | ||
| Q1 25 | $3.3B | $3.4B | ||
| Q4 24 | $3.3B | $3.3B | ||
| Q3 24 | $2.1B | $3.1B | ||
| Q2 24 | $2.1B | $3.0B |
股东权益ASGRY
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $1.7B | ||
| Q3 25 | $6.4B | $1.7B | ||
| Q2 25 | $6.1B | $1.7B | ||
| Q1 25 | $6.0B | $1.7B | ||
| Q4 24 | $5.9B | $1.8B | ||
| Q3 24 | $5.9B | $1.9B | ||
| Q2 24 | $6.2B | $2.0B |
总资产ASGRY
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $8.1B | ||
| Q3 25 | $12.2B | $7.9B | ||
| Q2 25 | $12.2B | $8.0B | ||
| Q1 25 | $11.9B | $7.9B | ||
| Q4 24 | $11.8B | $7.9B | ||
| Q3 24 | $11.0B | $7.5B | ||
| Q2 24 | $10.9B | $7.5B |
负债/权益比ASGRY
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 2.10× | ||
| Q3 25 | 0.53× | 2.00× | ||
| Q2 25 | 0.55× | 1.98× | ||
| Q1 25 | 0.56× | 1.98× | ||
| Q4 24 | 0.57× | 1.83× | ||
| Q3 24 | 0.36× | 1.63× | ||
| Q2 24 | 0.34× | 1.56× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $103.4M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $90.6M |
| 自由现金流率自由现金流/营收 | 9.7% | 10.2% |
| 资本支出强度资本支出/营收 | 5.2% | 1.4% |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | $195.6M |
8季度趋势，按日历期对齐
经营现金流ASGRY
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $103.4M | ||
| Q3 25 | $362.0M | $83.6M | ||
| Q2 25 | $221.0M | $81.3M | ||
| Q1 25 | $431.0M | $6.0M | ||
| Q4 24 | $481.0M | $111.4M | ||
| Q3 24 | $452.0M | $65.2M | ||
| Q2 24 | $333.0M | $82.8M |
自由现金流ASGRY
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $90.6M | ||
| Q3 25 | $259.0M | $63.8M | ||
| Q2 25 | $107.0M | $57.9M | ||
| Q1 25 | $334.0M | $-16.7M | ||
| Q4 24 | $388.0M | $89.1M | ||
| Q3 24 | $360.0M | $45.0M | ||
| Q2 24 | $230.0M | $55.9M |
自由现金流率ASGRY
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 10.2% | ||
| Q3 25 | 14.9% | 7.8% | ||
| Q2 25 | 6.4% | 7.0% | ||
| Q1 25 | 19.9% | -2.2% | ||
| Q4 24 | 22.8% | 10.3% | ||
| Q3 24 | 22.8% | 5.8% | ||
| Q2 24 | 14.6% | 7.3% |
资本支出强度ASGRY
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 1.4% | ||
| Q3 25 | 5.9% | 2.4% | ||
| Q2 25 | 6.8% | 2.8% | ||
| Q1 25 | 5.8% | 2.9% | ||
| Q4 24 | 5.5% | 2.6% | ||
| Q3 24 | 5.8% | 2.6% | ||
| Q2 24 | 6.5% | 3.5% |
现金转化率ASGRY
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
SGRY
| Private Insurance | $460.5M | 52% |
| Government Revenue | $368.6M | 42% |
| Other | $19.8M | 2% |
| Self Pay Revenue | $19.6M | 2% |
| Other Patient Service Revenue Sources | $16.5M | 2% |
